Beyond Air (XAIR) Stock Price, News & Analysis

Company Overview

Beyond Air, Inc. is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity. Beyond Air is also evaluating LungFit® PT for pulmonary tuberculosis and LungFit® C for viral and bacterial lung infections, including potential applications in acute respiratory distress syndrome. These programs position the LungFit platform as a versatile therapy that may complement or improve upon existing treatment options.

Beyond Air operates primarily in the United States and collaborates with academic and clinical research centers to advance its clinical trials. The company engages with regulatory authorities, including the U.S. Food and Drug Administration, to pursue marketing approvals and expanded indications for its nitric oxide therapies. By building strategic partnerships, Beyond Air aims to broaden access to its platform technology across diverse healthcare markets.

Founded in 2013 and headquartered in East Setauket, New York, Beyond Air is led by President and Chief Executive Officer Nicholas E. Caputo, a life sciences executive with extensive experience in medical device development and regulatory strategy. Under his leadership, the company has advanced multiple product candidates through early-stage clinical evaluation and continues to build a pipeline of inhaled gas therapies designed to improve outcomes for patients with challenging respiratory conditions.

Key Stats

• Today's Range: $2.30 to $2.44
• 50-Day Range: $2.06 to $4.20
• 52-Week Range: $2.02 to $13.52
• Volume: 324,507 shs
• Average Volume: 1.16 million shs
• Market Capitalization: $12.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Strong Buy

Beyond Air Stock Analysis - MarketRank™

Beyond Air scored higher than 88% of companies evaluated by MarketBeat, and ranked 127th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Beyond Air has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Beyond Air has a consensus price target of $11.00, representing about 355.5% upside from its current price of $2.42.

Amount of Analyst Coverage

Beyond Air has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beyond Air are expected to grow in the coming year, from ($0.79) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beyond Air is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beyond Air is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beyond Air has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.59% of the float of Beyond Air has been sold short.

Short Interest Ratio / Days to Cover

Beyond Air has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beyond Air has recently decreased by 29.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beyond Air does not currently pay a dividend.

Dividend Growth

Beyond Air does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -0.91

Percentage of Shares Shorted

7.59% of the float of Beyond Air has been sold short.

Short Interest Ratio / Days to Cover

Beyond Air has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beyond Air has recently decreased by 29.09%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.64

News Sentiment

Beyond Air has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Beyond Air this week, compared to 2 articles on an average week.

Search Interest

24 people have searched for XAIR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Beyond Air insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.40% of the stock of Beyond Air is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.50% of the stock of Beyond Air is held by institutions.

XAIR Stock Analysis - Frequently Asked Questions

How have XAIR shares performed this year?

Beyond Air's stock was trading at $7.17 on January 1st, 2025. Since then, XAIR shares have decreased by 66.3% and is now trading at $2.4150.

How were Beyond Air's earnings last quarter?

Beyond Air, Inc. (NASDAQ:XAIR) released its earnings results on Tuesday, August, 12th. The company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.50) by $0.03. The business had revenue of $1.76 million for the quarter, compared to analysts' expectations of $1.75 million. Beyond Air had a negative net margin of 880.72% and a negative trailing twelve-month return on equity of 232.61%.
Read the conference call transcript.

When did Beyond Air's stock split?

Beyond Air's stock reverse split on the morning of Monday, July 14th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Beyond Air's major shareholders?

Beyond Air's top institutional shareholders include Geode Capital Management LLC (18.07%), Wealth Effects LLC (0.32%) and Osaic Holdings Inc. (3.11%). Insiders that own company stock include Robert Carey, Steven A Lisi, Amir Avniel, Ron Bentsur, Michael A Gaul, Erick Lucera and Yoori Lee.
View institutional ownership trends.

How do I buy shares of Beyond Air?

Shares of XAIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Beyond Air own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Beyond Air investors own include Pfizer (PFE), NVIDIA (NVDA), General Motors (GM), Meta Platforms (META), Corbus Pharmaceuticals (CRBP), Norwegian Cruise Line (NCLH) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:XAIR
• CIK: 1641631
• Web: www.beyondair.net
• Phone: (516) 665-8200
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Beyond Air: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +359.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.62 million
• Net Margins: -880.72%
• Pretax Margin: -909.70%
• Return on Equity: -232.61%
• Return on Assets: -115.92%

Debt

• Debt-to-Equity Ratio: 0.92
• Current Ratio: 3.24
• Quick Ratio: 2.71

Sales & Book Value

• Annual Sales: $3.70 million
• Price / Sales: 3.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.32 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 5,230,000
• Free Float: 4,212,000
• Market Cap: $12.53 million
• Optionable: Optionable
• Beta: 0.28